References
- Akolekar R, Syngelaki A, Sarquis R, et al. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn. 2011;31(1):66–74.
- RCOG. The investigation and management of the small for gestational age fetus. Green top guideline number 312013.
- Kuc S, Wortelboer EJ, van Rijn BB, et al. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv. 2011;66(4):225–239.
- Allen R, Marleen S, Velauthar L, et al. Improved early prediction of preterm preeclampsia by combining second trimester maternal serum alpha fetoprotein and uterine artery Doppler. Journal of clinical. Gynecol Obstet. 2014;3(1):22–29.
- Allen R, Marleen S, Velauthar L, et al. The relationship between second trimester alpha fetoprotein levels and adverse pregnancy outcome. Open J Obstet Gynecol. 2013;3:262–266.
- Allen RE, Rogozinska E, Cleverly K, et al. Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014;182:194–201.
- Costa SL, Proctor L, Dodd JM, et al. Screening for placental insufficiency in high-risk pregnancies: is earlier better? Placenta. 2008;29(12):1034–1040.
- Khalil A, Akolekar R, Syngelaki A, et al. Maternal hemodynamics in normal pregnancies at 11–13 weeks’ gestation. Fetal Diagn Ther. 2012;32(3):179–185.
- Akolekar R, Zaragoza E, Poon LCY, et al. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2008;32(6):732–739.
- Akolekar R, Minekawa R, Veduta A, et al. Maternal plasma inhibin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009;29(8):753–760.
- Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004;191(4):1446–1451.
- Zhong Y, Tuuli M, Odibo AO. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenat Diagn. 2010;30(4):293–308.
- Goetzinger KR, Singla A, Gerkowicz S, et al. Predicting the risk of pre-eclampsia between 11 and 13 weeks’ gestation by combining maternal characteristics and serum analytes, PAPP-A and free beta-hCG. Prenat Diagn. 2010;30(12–13):1138–1142.
- Poon LCY, Maiz N, Valencia C, et al. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol. 2009;33(1):23–33.
- Spencer K, Yu CK, Cowans NJ, et al. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn. 2005;25(10):949–953.
- Odibo AO, Zhong Y, Goetzinger KR, et al. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta. 2011;32(8):598–602.
- Yaron Y, Ochshorn Y, Heifetz S, et al. First trimester maternal serum free human chorionic gonadotropin as a predictor of adverse pregnancy outcome. Fetal Diagn Ther. 2002;17(6):352–356.
- Madazli R, Bulut B, Tuten A, et al. First-trimester maternal serum metastin, placental growth factor and chitotriosidase levels in pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2012;164(2):146–149.
- Noori M, Donald AE, Angelakopoulou A, et al. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation. 2010;122(5):478–487.
- Vatten LJ, Åsvold BO, Eskild A. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction. Acta Obstet Gynecol Scand. 2012;91(12):1388–1394.
- Wortelboer EJ, Koster MP, Cuckle HS, et al. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia. BJOG. 2010;117(11):1384–1389.
- Dugoff L, Hobbins JC, Malone FD, et al. FASTER Trial Research Consortium. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005;106(2):260–267.
- Walters BN, Lao T, Smith V, et al. Alpha-fetoprotein elevation and proteinuric pre-eclampsia. BJOG. 1985;92(4):341–344.
- Williams MA, Hickok DE, Zingheim RW, et al. Elevated maternal serum alpha fetoprotein levels and midtrimester placental abnormalities in relation to subsequent adverse pregnancy outcomes. Am J Obstet Gynecol. 1992;167(4 Pt 1):1032–1037.
- Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–683.
- Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004;95(9):884–891.
- Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–658.
- Stepan H, Unversucht A, Wessel N, et al. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007;49(4):818–824.
- Khalil A, Akolekar R, Syngelaki A, et al. Maternal hemodynamics at 11–13 weeks’ gestation and risk of pre-eclampsia. Ultrasound Obstet Gynecol. 2012;40(1):28–34.
- Poon LC, Kametas NA, Maiz N, et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53(5):812–818.
- Khalil A, Sodre D, Syngelaki A, et al. Maternal hemodynamics at 11–13 weeks of gestation in pregnancies delivering small for gestational age neonates. Fetal Diagn Ther. 2012;32(4):231–238.